{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:55:45Z","timestamp":1793404545965,"version":"4.5.0"},"reference-count":61,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Respiratory tract infection, most often involving opportunistic bacterial species with broad-spectrum antibiotic resistance, is the primary cause of death in persons with cystic fibrosis (CF). Species within the\n            <jats:italic>Burkholderia cepacia<\/jats:italic>\n            complex are especially problematic in this patient population. We investigated a novel surfactant-stabilized oil-in-water nanoemulsion (NB-401) for activity against 150 bacterial isolates recovered primarily from CF respiratory tract specimens. These specimens included 75\n            <jats:italic>Burkholderia<\/jats:italic>\n            isolates and 75 isolates belonging to other CF-relevant species including\n            <jats:italic>Pseudomonas<\/jats:italic>\n            ,\n            <jats:italic>Achromobacter<\/jats:italic>\n            ,\n            <jats:italic>Pandoraea<\/jats:italic>\n            ,\n            <jats:italic>Ralstonia<\/jats:italic>\n            ,\n            <jats:italic>Stenotrophomonas<\/jats:italic>\n            , and\n            <jats:italic>Acinetobacter<\/jats:italic>\n            . Nearly one-third of the isolates were multidrug resistant, and 20 (13%) were panresistant based on standard antibiotic testing. All isolates belonging to the same species were genotyped to ensure that each isolate was a distinct strain. The MIC\n            <jats:sub>90<\/jats:sub>\n            of NB-401 was 125 \u03bcg\/ml. We found no decrease in activity against multidrug-resistant or panresistant strains. MBC testing showed no evidence of tolerance to NB-401. We investigated the activity of NB-401 against a subset of strains grown as a biofilm and against planktonic strains in the presence of CF sputum. Although the activity of NB-401 was decreased under both conditions, the nanoemulsion remained bactericidal for all strains tested. These results support NB-401's potential role as a novel antimicrobial agent for the treatment of infection due to CF-related opportunistic pathogens.\n          <\/jats:p>","DOI":"10.1128\/aac.00691-08","type":"journal-article","created":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T00:26:04Z","timestamp":1225153564000},"page":"249-255","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":48,"title":["In Vitro Activities of a Novel Nanoemulsion against\n            <i>Burkholderia<\/i>\n            and Other Multidrug-Resistant Cystic Fibrosis-Associated Bacterial Species"],"prefix":"10.1128","volume":"53","author":[{"given":"John J.","family":"LiPuma","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Communicable Diseases"},{"name":"Michigan Nanotechnology Institute for Medicine and the Biological Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivaprakash","family":"Rathinavelu","sequence":"additional","affiliation":[{"name":"Michigan Nanotechnology Institute for Medicine and the Biological Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget K.","family":"Foster","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Communicable Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan C.","family":"Keoleian","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Communicable Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Makidon","sequence":"additional","affiliation":[{"name":"Michigan Nanotechnology Institute for Medicine and the Biological Sciences"},{"name":"Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Kalikin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Communicable Diseases"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"James R.","family":"Baker","sequence":"additional","affiliation":[{"name":"Michigan Nanotechnology Institute for Medicine and the Biological Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1046\/j.1365-2672.1999.00486.x","volume":"28","year":"1999","unstructured":"Ayres, H. M., J. R. Furr, and A. D. Russell. 1999. Effect of permeabilizers on antibiotic sensitivity of Pseudomonas aeruginosa. Lett. Appl. Microbiol.28:13-16.","journal-title":"Lett. Appl. Microbiol."},{"key":"e_1_3_2_3_2","unstructured":"Nanoemulsion vaccines. 2008"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/140.6.1650"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/377541"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-1097(03)00724-9"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00070-07"},{"key":"e_1_3_2_8_2","first-page":"81","year":"2007","unstructured":"Burns, J. L. 2007. Antibiotic resistance of Burkholderia spp, p. 81-91. In T. Coenye and P. Vandamme (ed.), Burkholderia: molecular biology and genomics. Horizon Press, Wymondham, United Kingdom.","journal-title":"Burkholderia: molecular biology and genomics"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1378\/chest.116.3.775","volume":"116","year":"1999","unstructured":"Campbell, P. W., III, and L. Saiman. 1999. Use of aerosolized antibiotics in patients with cystic fibrosis. Chest116:775-788.","journal-title":"Chest"},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10096-007-0256-x","volume":"26","year":"2007","unstructured":"Caraher, E., G. Reynolds, P. Murphy, S. McClean, and M. Callaghan. 2007. Comparison of antibiotic susceptibility of Burkholderia cepacia complex organisms when grown planktonically or as biofilm in vitro. Eur. J. Clin. Microbiol. Infect. Dis.26:213-216.","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki217"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(01)37026-X"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2001.118430"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0001-706X(03)00120-7","volume":"87","year":"2003","unstructured":"Chepurnov, A. A., L. F. Bakulina, A. A. Dadaeva, E. N. Ustinova, T. S. Chepurnova, and J. R. Baker, Jr. 2003. Inactivation of Ebola virus with a surfactant nanoemulsion. Acta Trop.87:315-320.","journal-title":"Acta Trop."},{"key":"e_1_3_2_15_2","unstructured":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2006"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/340279"},{"key":"e_1_3_2_17_2","first-page":"77","volume":"149","year":"2002","unstructured":"Coenye, T., and J. J. LiPuma. 2002. Population structure analysis of Burkholderia cepacia genomovar III: varying degrees of genetic recombination characterize major clonal complexes. Microbiology149:77-88.","journal-title":"Microbiology"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.2.153"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043891"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","volume":"354","year":"2006","unstructured":"Elkins, M. R., M. Robinson, B. R. Rose, C. Harbour, C. P. Moriarty, G. B. Marks, E. G. Belousova, W. Xuan, and P. T. Bye. 2006. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N. Engl. J. Med.354:229-240.","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1006\/mpat.2001.0487"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200208-855OC"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1378\/chest.119.5.1521","volume":"119","year":"2001","unstructured":"Grebski, E., C. Peterson, and T. C. Medici. 2001. Effect of physical and chemical methods of homogenization on inflammatory mediators in sputum of asthma patients. Chest119:1521-1525.","journal-title":"Chest"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1046\/j.1365-2672.2000.01127.x","volume":"89","year":"2000","unstructured":"Hamouda, T., and J. R. Baker, Jr. 2000. Antimicrobial mechanism of action of surfactant lipid preparations in enteric gram-negative bacilli. J. Appl. Microbiol.89:397-403.","journal-title":"J. Appl. Microbiol."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/315124"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1078\/0944-5013-00069"},{"key":"e_1_3_2_27_2","unstructured":"Cosmetic and drug preservation: principles and practices 1984"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1089\/jam.2007.0603","volume":"20","year":"2007","unstructured":"Hasan, M. A., and C. F. Lange. 2007. Estimating in vivo airway surface liquid concentration in trials of inhaled antibiotics. J. Aerosol Med.20:282-293.","journal-title":"J. Aerosol Med."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.1.34"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.32.4.924-930.1994"},{"key":"e_1_3_2_31_2","first-page":"AB83","volume":"58","year":"2008","unstructured":"Jones, T., M. Flack, M. M. Ijzerman, and J. R. Baker, Jr. 2008. Safety, tolerance, and pharmacokinetics of topical nanoemulsion (NB-002) for the treatment of onychomycosis. J. Am. Acad. Dermatol.58(Suppl. 2):AB83.","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_2_32_2","doi-asserted-by":"crossref","first-page":"AB93","DOI":"10.1016\/j.jaad.2006.12.012","volume":"58","year":"2008","unstructured":"Jones, T., M. Flack, L. Stanberry, and J. R. Baker, Jr. 2008. Safety, tolerance, pharmacokinetics, and efficacy of topical nanoemulsion (NB-001) for the treatment of herpes labialis. J. Am. Acad. Dermatol.58(Suppl. 2):AB93.","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2672.2004.02135.x"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.1.123"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3062.2001.003003149.x"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcp.0000181475.85187.ed"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002954"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.3.9707010"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.30.6.923"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2007.12.001"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/ppul.20671","volume":"42","year":"2007","unstructured":"Moriarty, T. F., J. C. McElnay, J. S. Elborn, and M. M. Tunney. 2007. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection. Pediatr. Pulmonol.42:1008-1017.","journal-title":"Pediatr. Pulmonol."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.42.5.1915-1922.2004"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00381-5"},{"key":"e_1_3_2_44_2","first-page":"195","volume":"155","year":"2001","unstructured":"Myc, A., T. Vanhecke, J. J. Landers, T. Hamouda, and J. R. Baker, Jr. 2001. The fungicidal activity of novel nanoemulsion (X8W60PC) against clinically important yeast and filamentous fungi. Mycopathologia155:195-201.","journal-title":"Mycopathologia"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2007.11.010"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn072"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.7.2612-2617.2005"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00799-07"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.6.2926-2928.2005"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-50-6-535"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.70.8.4547-4555.2002"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/35037627"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(88)80165-3"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-7012(00)00122-6"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05321-1"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007504524034"},{"key":"e_1_3_2_57_2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/jac\/dkm207","volume":"60","year":"2007","unstructured":"Taneja, N. K., and J. S. Tyagi. 2007. Resazurin reduction assays for screening of anti-tubercular compounds against dormant and actively growing Mycobacterium tuberculosis,Mycobacterium bovis BCG and Mycobacterium smegmatis. J. Antimicrob. Chemother.60:288-293.","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_2_58_2","unstructured":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.19.1.3137"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1128\/mr.56.3.395-411.1992"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1099\/00207713-47-4-1188"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00138-07"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00691-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00691-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:46:33Z","timestamp":1645472793000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00691-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1128\/AAC.00691-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.00691-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"2008-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-10-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}